Hepatitis, Viral, Human  >>  CTS-1027  >>  Phase 2
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
CTS-1027 / Histogen
NCT00570336: Study of CTS-1027 in Hepatitis C Patients

Completed
2
87
US
CTS-1027, Placebo
Conatus Pharmaceuticals Inc., FGK Clinical Research GmbH
Chronic Hepatitis C Virus Infection
07/09
07/09
NCT00925990: CTS-1027 in Interferon-Naive Hepatitis C Patients

Completed
2
70
US
ribavirin, Copegus, CTS-1027, Placebo for ribavirin
Conatus Pharmaceuticals Inc.
Hepatitis C
05/10
07/10
NCT01273064: Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders

Terminated
2
114
US
CTS-1027, pegylated interferon, Pegasys, Ribavirin, Copegus, Placebo
Conatus Pharmaceuticals Inc.
Hepatitis C
09/11
10/11
CTS-1027-04, NCT01051921: Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders

Completed
2
67
US
CTS-1027, Pegylated interferon, Pegasys, Ribavirin, Copegus
Conatus Pharmaceuticals Inc.
Hepatitis C
11/11
12/11

Download Options